Psychiatry
Pimavanserin: A Novel Drug Approved to Treat Parkinson’s Disease Psychosis
by Amanda K. Kitten, PharmD; Sarah A. Hallowell, PharmD; Stephen Saklad, PharmD, BCPP; and Kirk E. Evoy, PharmD, BCACP, BC-ADM, CTTS Drs. Kitten, Hallowell, Saklad, and Evoy are with the College of Pharmacy, The University of Texas at Austin in Austin, Texas. Innov Clin Neurosci. 2017;15(1–2):16–22
Effectiveness of Electroconvulsive Therapy (ECT) in Parkinsonian Symptoms: A Case Series
by Sandeep Grover, MD; Aditya Somani, MD; Neeru Sahni, MD; Sahil Mehta, DM; Swati Choudhary, MBBS; Rahul Kumar Chakravarty, MBBS; and Anju Moni Rabha, MBBS Drs. Grover, Somani, Sahni, Mehta, Choudhary, Chakravarty, and Rabha are with the Post Graduate Institute of Medical Education and Research, Chadigarh in Chandigarh, India. Innov Clin Neurosci. 2017;15(1–2):23–27
Precursors to the PANSS: The BPRS and its progenitors
by Nina R. Schooler, PhD Dr. Schooler is Professor of Psychiatry at SUNY Downstate Medical Center in Brooklyn, New York. Funding: No funding was provided for this article. Disclosures: The author has no financial conflicts relevant to the content of this article. Abstract: The systematic assessment of signs and symptoms of psychopathology has roots that […]
A Developmental History of the Positive and Negative Syndrome Scale (PANSS)
by Stacy Liechti, PhD; Gianna Capodilupo, MA; Douglas J. Opler, MD; Mark Opler, PhD, MPH; and Lawrence H. Yang, PhD Dr. Liechti is Lead Research Consultant at the PANSS Institute in New York, New York. Ms. Capodilupo is Research Assistant at MedAvante-ProPhase in New York, New York. Dr. D. Opler is Assistant Professor in the […]
Using the Positive and Negative Syndrome Scale (PANSS) to Define Different Domains of Negative Symptoms: Prediction of Everyday Functioning by Impairments in Emotional Expression and Emotional Experience
by Philip D. Harvey, PhD; Anzalee Khan, PhD; and Richard S. E. Keefe, PhD Dr. Harvey is Professor of Psychiatry and Behavioral Sciences at University of Miami School of Medicine in Miami, Florida. Dr. Khan is Senior Biostatistician at NeuroCog Trials and holds an appointment in the Psychopharmacology Research Program at the Nathan S. Kline […]
Insight and Treatment Outcomes in Schizophrenia: Post-hoc Analysis of a Long-term, Double-blind Study Comparing Lurasidone and Quetiapine XR
by Philip D. Harvey, PhD; Cynthia O. Siu, PhD; and Antony D. Loebel, MD Dr. Harvey is with the University of Miami Miller School of Medicine in Miami, Florida, and the Research Service of the Bruce W. Carter VA Medical Center in Miami, Florida. Dr. Siu is with COS and Associates Ltd. in Central District, […]
Negative Symptom Dimensions of the Positive and Negative Syndrome Scale Across Geographical Regions: Implications for Social, Linguistic, and Cultural Consistency
by Anzalee Khan, PhD; Lora Liharska, MS; Philip D. Harvey, PhD; Alexandra Atkins, PhD; Daniel Ulshen, BA; and Richard S.E. Keefe, PhD Dr. Khan is Senior Biostatistician at NeuroCog Trials and holds an appointment in the Psychopharmacology Research Program at the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, New York. Ms. Liharska is […]
Disparity between General Symptom Relief and Remission Criteria in the Positive and Negative Syndrome Scale (PANSS): A Post-treatment Bifactor Item Response Theory Model
by Ariana E. Anderson, PhD; Steven P. Reise, PhD; Stephen R. Marder, MD; Maxwell Mansolf, MS; Carol Han, BS; and Robert M. Bilder, PhD Dr. Anderson is with the Department of Psychiatry and Biobehavioral Sciences and the Department of Statistics, Dr. Reise is with the Department of Psychology, Dr. Marder is with the Department of […]
